Published • loading... • Updated
Merck, Wellcome Partner with Global Health Group to Make Ebola Vaccine for Clinical Trials
The collaboration is backed by up to $8.5 million from CEPI and aims to produce doses for early-stage testing.
- On Thursday, the Coalition for Epidemic Preparedness Innovations announced an $8.5 million commitment to Singapore-based Hilleman Laboratories to manufacture doses of an experimental Bundibugyo Ebola vaccine for clinical trials.
- The Bundibugyo strain currently lacks any licensed vaccine, fueling a fast-spreading outbreak in the Democratic Republic of the Congo that officials describe as a humanitarian crisis.
- Hilleman Laboratories will use material developed by the International AIDS Vaccine Initiative to produce doses, building on the manufacturing process for Merck's Zaire Ebola vaccine.
- CEPI Chief Executive Richard Hatchett said "with Bundibugyo virus cases rising at worrying speed, the epidemic is fast becoming a humanitarian crisis." Full production takes roughly 6 months, though trial doses should arrive sooner.
- Beyond this effort, CEPI is investing up to $8.6 million in an Oxford University vaccine candidate now in human trials and has committed up to $50 million for a Moderna collaboration.
Insights by Ground AI
14 Articles
14 Articles
Ebola Vaccine Race Accelerates as Congo Outbreak Outpaces Response
·New York, United States
Read Full Article
Ebola outbreak sparks global vaccine race
The Ebola outbreak in Central Africa has sparked a vaccine race as scientists vie to stop an outbreak that threatens to become the biggest ever. Health workers fighting to contain the spread of the Bundibugyo strain have been hampered by a lack of medical equipment, widespread misinformation, and, critically, the lack of a vaccine. The Coalition for Epidemic Preparedness Innovations is financing the first clinical trials for an experimental jab …
·New York, United States
Read Full Article
A vaccine against Ebola, presented by WHO as "the most promising" against the epidemic still raging in the Democratic Republic of the Congo, will be developed by Hilleman Laboratories, based in Singapore, announced this group on Thursday. ...
·Brussels, Belgium
Read Full ArticleCoverage Details
Total News Sources14
Leaning Left2Leaning Right2Center8Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
L 17%
C 67%
R 16%
Factuality
To view factuality data please Upgrade to Premium
